# Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative

> **NCT02754011** · PHASE1 · COMPLETED · sponsor: **UNICANCER** · enrollment: 18 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Combination of ribociclib + capecitabine

## Key facts

- **NCT ID:** NCT02754011
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-02
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-12-23
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02754011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02754011, "Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02754011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*